key: cord-0717679-gcttlpxm
authors: Kiprov, Dobri; Conboy, Michael J.; Conboy, Irina M.
title: Immunomodulation for the Management of Corona Virus Disease (COVID-19)
date: 2020-06-27
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2020.102856
sha: 760ba0aa8afa7b51cbfa60bb1b7eef1ecea3546f
doc_id: 717679
cord_uid: gcttlpxm

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Dobri D. Kiprov Currently there is no vaccine for prophylaxis nor proven treatment for COVID-19.

Immune or convalescent plasma collected from people who have fully recovered from infection contains antibodies against the infectious agent. Convalescent plasma provides passive immunity and has been used for the prophylaxis and treatment of a number of infectious diseases, including recent epidemics with SARS-Cov-1, Ebola and Middle Eastern Respiratory Syndrome (MERS). 1 Small studies from China have demonstrated that infusion of convalescent plasma from people who have recovered from COVID-19 is safe and results in reduction of viral load and improved clinical outcome. This prompted the FDA to allow the use of convalescent plasma in patients with COVID-19. 1 The proposed infusion dose is 200 ml of plasma. However, this is based on the Chinese experience alone and deserves further study.

Older adults and people with severe underlying conditions are at higher risk for developing more serious complications from COVID-19 and account for the majority of the deaths. Systemic chronic inflammation is believed to be the major cause of immunosenescence. A prominent feature of the aging phenotype is increased secretion of proinflammatory cytokines which may contribute to the cytokine storm seen in COVID-19. Older adults experience down regulation of the immune response that leads to an increased susceptibility to viral infections and weakened response to vaccines. Collateral damage from chronic inflammation is oxidative stress. 2 Experimental studies in rodents using parabiosis and blood exchange models have demonstrated that the removal of proinflammatory substances from the circulation of old mice leads to a rapid and robust rejuvenation of multiple organs. 3 Since parabiosis is not possible in humans, therapeutic plasma exchange, (TPE) has been proposed as an alternative because it has a multifaceted immunomodulatory effect. 4 TPE has been shown in randomized and nonrandomized clinical trials to have a beneficial effect in sepsis associated with severe inflammatory response syndrome (SIRS). 5 And recently, TPE has been successfully used in the treatment of severe cytokine release syndrome after Chimera Antigen Receptor T cell (CAR-T) infusion. TPE with 5% albumin replacement also provides a significant antioxidant boost. 5 We believe that TPE with a combination of 5% albumin and convalescent plasma replacement at the end of the procedure can be a valuable treatment option for COVID-19 patients and warrants a comparison trial with simple convalescent plasma infusion.

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Covid-19 and Immunity in Aging Populations -A New Research Agenda

A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood

Intermittent Heterochronic Plasma Exchange as a Modality for Delaying Cellular Senescence -A Hypothesis

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19